Trusted by 10,000+ Scientists Since 2002. View Our 5-Star Google Review, Select Citations and 4,000+ Citations at Google Scholar.

Recent Advances In Recombinant Antibody Production Technology

Nov 2nd 2023

Recent Advances In Recombinant Antibody Production Technology

It's now more than three decades (counting from 1989) since the US FDA and the United States Food and Drug Administration approved the first monoclonal antibodies. During this period, antibody engineering has constantly evolved.

Because of the adoption of the latestantibody production methods and specificity, today's antibodies pose fewer adverse effects, positioning them as one of the best-selling medications in the pharmaceutical market. The global antibody market stands at $237 billion in 2023 and will reach $834billion in 2033, growing at 13.4% CAGR, as determined by Future Market Insights.

The recombinant antibody is the newest yet most advancing antibody in the market today. Ideally, technologies have considerably contributed to recombinant antibody production and optimization.

Some of these advancements include the generation of hybridomas, Antibody Sequencing Services, deep sequencing, protein display technologies, Peptide Synthesis Services, and DNA technology in antibody production. Combining these technologies in antibody production has enhancedantibody discovery platforms and optimization of recombinant antibodies to be a successful and standard endeavor.

This article will look at the recent advances in recombinant antibody production technology and anything related to recombinant antibody engineering.

We'll start with the basics!

What is Antibody?

Recombinant antibody production

Recombinant is an antibody, right? So, before focusing on recombinant antibody production technologies, it's essential to understand what an antibody is, what antibody sequencing services are, plus antibody sequencing companies and any other basic but necessary information.

Antibodies, known as immunoglobulins, are Y-shaped peptide molecules secreted by b cells, primarily differentiated by plasma cells. The basic function of antibodies is to stop and control pathogens while typically improving the immune response.

Moreover, antibody production facilitates protection against intoxication and infection by action techniques for antibody functionalities, such as agonism, antagonism, lysosomal-related PCD, apoptosis PCD, ADCP, ADCC cell killing, and CDC.

As stated earlier, the history ofantibody engineering and production dates back to the 1980s. This time, scientists were exploring the likelihood of using antibodies as therapeutics.

One significant milestone in this stage was employing hybridoma technology and natural sources, like animal blood, used as diagnostic agents. This facilitated the production of monoclonal antibodies through fusing B cells, enhancing single antibody type and a myeloma cell.


While the production of feasible antibodies was possible in this stage, it was often restricted because many hybridomas were considerably low-yielding and unstable, and proper myeloma cell lines were unavailable.

For this reason, antibody discovery, a fundamental aspect that widens clinical applications and research, was critically birthing recombinant antibody production, ideally to improve antibody engineering opportunities and experimental reproducibility.

So, let's now delve into recombinant antibodies!

What are Recombinant Antibodies?